Table 2 Multivariable analysis of prognostic factors in EC patients.
Characteristics | 5-year OS | 5-year RFS | ||
|---|---|---|---|---|
HR (95%CI) | p | HR (95%CI) | p | |
Age | ||||
< 54 | Reference | Reference | ||
≥ 54 | 1.080(0.725–1.609) | 0.706 | 0.980(0.734–1.307) | 0.889 |
FIGO stage | 0.036* | 0.014* | ||
I | Reference | Reference | ||
II | 0.938(0.330–2.663) | 0.904 | 0.258(0.097–0.688) | 0.007* |
III | 2.344(0.662-8.300) | 0.187 | 0.334(0.110–1.013) | 0.053 |
Pathological type | ||||
Endometrioid adenocarcinoma | Reference | Reference | ||
Other types | 1.531(1.004–2.334) | 0.048* | 1.237(0.865–1.769) | 0.243 |
Histologic grade | 0.125 | 0.040* | ||
G1 | Reference | Reference | ||
G2 | 1.956(0.964–3.969) | 0.063 | 1.651(1.078–2.530) | 0.021* |
G3 | 1.986(1.010–3.903) | 0.047* | 1.616(1.074–2.431) | 0.021* |
Molecular classification | < 0.001* | < 0.001* | ||
POLEmut | Reference | Reference | ||
MMRd/MSI-H | 2.623(0.977–7.039) | 0.056 | 1.719(1.086–2.720) | 0.021* |
NSMP | 3.117(1.139–8.529) | 0.027* | 1.750(1.079–2.838) | 0.023* |
p53abn | 10.875(4.568–25.892) | < 0.001* | 3.020(2.009–4.540) | < 0.001* |
Myometrial invasion | ||||
< 1/2 | Reference | Reference | ||
≥ 1/2 | 0.594(0.249–1.416) | 0.240 | 1.422(0.693–2.918) | 0.337 |
LVSI | ||||
Ly0/Ly1 | Reference | Reference | ||
Substantial | 1.691(0.740–3.861) | 0.212* | 4.680(2.183–10.033) | < 0.001* |
ER | ||||
Positive (+) | Reference | Reference | ||
Negative (-) | 1.483(0.880–2.500) | 0.139 | 1.089(0.780–1.520) | 0.617 |
PR | ||||
Positive (+) | Reference | Reference | ||
Negative (-) | 2.149(1.313–3.518) | 0.002* | 1.176(0.853–1.620) | 0.323 |
Family history | ||||
Yes | Reference | Reference | ||
No | 1.316(0.716–2.417) | 0.377 | 1.027(0.662–1.594) | 0.904 |
Smoking history | ||||
Yes | Reference | Reference | ||
No | 0.463(0.241–0.890) | 0.021* | 0.498(0.302–0.821) | 0.006* |
Adjuvant therapy | ||||
Yes | - | Reference | ||
No | - | - | 1.966(1.353–2.858) | < 0.001* |
